The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Studying determinants of resistance to anti-BCMA therapies in multiple myeloma
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses ongoing research into the genomic determinants of resistance to anti-BCMA therapies in multiple myeloma (MM). This research aims to identify genomic drivers that predict the response to certain therapies, allowing for more efficient treatment selection. Dr Maura highlights that some of these genomic drivers were acquired at relapse, and a change in therapeutic approach is likely required in these patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
